- Home
- RDVT vs VALN Comparison
RDVT vs VALN Comparison
Compare RDVT & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDVT
- VALN
- Stock Information
- Founded
- RDVT 2017
- VALN 2012
- Country
- RDVT United States
- VALN France
- Employees
- RDVT N/A
- VALN N/A
- Industry
- RDVT Computer Software: Prepackaged Software
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDVT Technology
- VALN Health Care
- Exchange
- RDVT Nasdaq
- VALN Nasdaq
- Market Cap
- RDVT 538.6M
- VALN 510.7M
- IPO Year
- RDVT N/A
- VALN 2021
- Fundamental
- Price
- RDVT $36.72
- VALN $6.79
- Analyst Decision
- RDVT
- VALN Strong Buy
- Analyst Count
- RDVT 0
- VALN 2
- Target Price
- RDVT N/A
- VALN $16.00
- AVG Volume (30 Days)
- RDVT 79.2K
- VALN 142.9K
- Earning Date
- RDVT 05-07-2025
- VALN 05-06-2025
- Dividend Yield
- RDVT 0.81%
- VALN N/A
- EPS Growth
- RDVT N/A
- VALN N/A
- EPS
- RDVT 0.50
- VALN N/A
- Revenue
- RDVT $75,189,000.00
- VALN $175,564,758.00
- Revenue This Year
- RDVT $15.93
- VALN $19.17
- Revenue Next Year
- RDVT $13.85
- VALN $26.31
- P/E Ratio
- RDVT $73.63
- VALN N/A
- Revenue Growth
- RDVT 24.89
- VALN 10.32
- 52 Week Low
- RDVT $16.56
- VALN $3.62
- 52 Week High
- RDVT $43.44
- VALN $9.50
- Technical
- Relative Strength Index (RSI)
- RDVT 47.11
- VALN 50.63
- Support Level
- RDVT $36.16
- VALN $6.54
- Resistance Level
- RDVT $37.93
- VALN $7.30
- Average True Range (ATR)
- RDVT 2.26
- VALN 0.48
- MACD
- RDVT 0.02
- VALN 0.01
- Stochastic Oscillator
- RDVT 64.23
- VALN 56.79
About RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in big data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses and assets.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.